Fig. 1


a
Rel. absorbance (in %)
120
100
80
60
40
20
0
Ctrl
WT
XVir
LY - + - -
PD - - + -
LEE - - - +
b
Viral titer
7
6
5
4
3
2
1
0
XVir
WT
- LEE LY PD
c
Rel. Fiber DNA
XVir
WT
LEE
LY
PD
hpi
24
36
48

Fig. 2


XVir
WT
PD (500nM) - + - + - +
hpi 12 12 24 24 36 36
E1A
E2A
E1B55k
actin
PD (500nM) - + - + - + -
hpi 24 24 36 36 48 48 72
Hexon
actin

Fig. 3


a
T24
RT112
253J
Rel. absorbance (%)
120
100
80
60
40
20
0
XVir - + - +
PD - - + +
b
T24
RT112
253J
Viral titer (fold change)
5,00
4,00
3,00
2,00
1,00
0,00
XVir + +
PD - +
c
647V
639V
Rel. absorbance (%)
120
100
80
60
40
20
0
XVir - + - +
PD - - + +
d
647V
639V
Viral titer
1,20
1,00
0,80
0,60
0,40
0,20
0,00
XVir + +
PD - +

Fig. 4


a
T24
b
UMUC3
- PD-0332991
+ PD-0332991
Norm. Fiber DNA
hpi
24
36
48
c
RT112
d
253J

Fig. 5

a


-WT
+WT
Relative absorbance (in %)
120
100
80
60
40
20
0
-
1dai
6hai
1hpi
PD-0332991

b


- XVir
+ XVir
Relative absorbance (in %)
120
100
80
60
40
20
0
-
1dai
6hai
1hpi
PD-0332991

Fig. 6


XVir-N-31 + PD
AD-WT + PD
AD-Delta24 +PD
XVir-E2FM+PD
PD-0332991
XVir-N-31
AD-WT
AD-Delta24
XVir-E2FM
Mock

Fig. 7


500 nM Palbociclib
- Palbociclib

Fig. 8


Viral DNA Replication of dl703 in UMUC3 infeted with 10 MOI
Rel. Fiber DNA
300,00
250,00
200,00
150,00
100,00
50,00
0,00
dl 703
Nutlin 3a + dl703
Lee + dl703
Cl1040 + dl703
Roscovitin + dl703
48H
2,93
20,47
275,44
28,36
28,15

Fig. 9A



Fig. 9B



Fig. 9C



Fig. 10


100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Mock
dl703
LEE011
LEE011 + dl703
Nutlin3a
Nutlin3a + dl703
CI1040
CI1040 + dl703
Roscovitine
Roscovitine + dl703
G2/M
S
G1

Fig. 11


+ Palbociclib
UMUC3-1 MOI
T24-50 MOI
RT122-10 MOI

Fig. 12


cell survival in %
1
0,9
0,8
0,7
0,6
0,5
0,4
0,3
0,2
0,1
0
w/o
15 nM PARPi
500 nM PD
15 nM PARPi + 500 nM PD
Inhibitor treatment
not infected
10 MOI XVir-N-31
50 MOI XVir-N-31

Fig. 13



Asterisks (*) indicate artefacts from cell fixing

Fig. 14


10 MOI XVir-N-31
w/o
160 nM PARPi
400 nM PD
160 nM PARPi 400 nM PD
1 dpi
2 dpi
3 dpi
4 dpi
5 dpi
6 dpi

Fig. 15


140
120
100
80
60
40
20
0
mock
10 MOI
20 MOI
40 MOI
500 nM PD
300 nM JQ1
PD+10 Moi
PD+20 MOI
PD+40 MOI
JQ1+10 MOI
JQ1+20 MOI
JQ1+40 MOI
JQ1+PD
JQ1+PD+10 MOI
JQ1+PD+20 MOI
JQ1+PD+40 MOI

Fig. 16


SK-N-MC
% living cells
100
50
0
XVir-N-31 only
+ abemaciclib 200nM
+ JQ1 500nM
+ abemaciclib 200nM + JQ1 500nM
mock
MOI 5
MOI 10
MOI 20

Fig. 17


LY-2835219 - 200 - 200 500 - 200 - 200 500
MK-1775 - - 200 200 - - - 200 200 -
Rb
pRb
E2F1
GAPDH
p21
after 24h treatment
after 48h treatment

Fig. 18


mock
MOI 5
MOI 10
MOI 20
% living cells
100
50
0
+ abemaciclib 200nM
+ adavosertib 200nM

Fig. 19


SK-N-MC
% of cells
100
50
0
G2/M
S
G0/G1
mock
abemaciclib 10nM
abemaciclib 50nM
abemaciclib 100nM
abemaciclib 200nM
abemaciclib 500nM
adavosertib 200nM
adavosertib 500nM
abemaciclib 200nM + adavosertib 200nM
abemaciclib 500nM + adavosertib 500nM

Fig. 20


120
100
80
60
40
20
0
E2F1 expression normalized to actin as % of sKCNTL transfected cells
100
25
27
37
Crtl
Hela
A549
T24

Fig. 21



Fig. 22



Fig. 23

Wild-type E2-early-promoter

5-AG**TTTTCGCGC**TTAAATTTGAGAAAG**GGCGCGAA**ACTAGTCCTT
3-TC**AAAAGCGCG**AATTTAAACTCTTTC**CCGCGCTT**TGATCAGGAA

5-AG**GAGTCGGAT**TTAAATTTGAGAAAG**TAATAGGT**ACTAGTCCTT
3-TC**CTCAGCCTA**AATTTAAACTCTTTC**ATTATCCA**TGATCAGGAA

Mutated E2-early-promoter

Fig. 24


E2-early at 24 hrs
Rel. mRNA expression Normalised to Actin
(In percent of control
34
32
30
8
6
4
2
0
ADWT-RGD
ADWT-E2FM
T24 MOI 20
A549 MOI 2
HeLaRDB MOI 10

Fig. 25

Abemaciclib



Palbociclib



Ribociclib



Fig. 25 (continued)

Dinaciclib



Fig. 26

Olaparib



Veliparib



Rucaparib



Fig. 27

(Taken from Montserrat Perez-Savia and Manel Esteller: Bromodomain inhibitors and cancer therapy: From structure to applications. EPIGENTCS 2017, 12, 323-339)

JQ1



OTX-015



Fig. 27 (continued)

I-BET151



CPI-0610





Fig. 27 (continued)

Fig. 28


WT-Ad5
E1A
E1B
E2
E3
E4
CR1
CR2
CR3
12S, 13S
1
40
80
120
139
188
289
dl520
CR1
CR2
12S
1
40
80
120
139
186
289

Fig. 29


12S, 13S
E1A
E1B
L1
L2
L3
L4
E3
RGD
fiber
E2
E4
E1B19K, E1B55K

Fig. 30



Ad-Delta 24 and Ad-Delta 24-RGD



Fig. 31



Fig. 32



Fig. 33


WT-Ad5
E1A
E1B
E2
E3
E4
CR1
CR2
CR3
12S, 13S
1
40
80
120
139
188
289
CB016
CR3
1
40
80
120
139
186
289

Fig. 34


C
Human Adenovirus serotype 5
ITR
E1A
E3/19K
Fiber
ITR
ATC GAT CTT ACC TGC CAC GAG GCT GGC TTT CCA
TAC AAA AGC AG
T T
P S
ACA ACT --- --- --- --- --- --- --- --- --- CCA TCT
ATC GAT --- --- --- --- --- --- --- --- --- TTT CCA
TAC AAA AAG CA
ACA ACT TGT GAC TGC CGC GGA GAC TGT TTC TGC CCA TCT
T T C D C R G D C F C P S
ITR
E1AΔ24
E3/19K445A
Fiber- RGD
ITR